Sermorelin
| Category | Growth Hormone Secretagogues |
| Goals | Recovery · Sleep |
| Evidence level | Clinical (historically approved drug; modern uses extrapolated) |
| Legal status | Prescription only — available via compounding pharmacies |
| FDA status | Formerly approved (Geref, 1997); brand withdrawn 2008–09; now compounded |
| Half-life | ~10–20 minutes (very short) |
| Routes | Subcutaneous |
| CAS / MW / Sequence | 86168-78-7 · ~3358 g/mol · 29-aa GHRH(1-29) amide |
| Last reviewed | 2026-06-05 |
In one line
A synthetic copy of the first 29 amino acids of human GHRH (the body’s own growth-hormone-releasing hormone) that prompts the pituitary to release its own growth hormone in a natural, pulsatile way — historically an FDA-approved drug, now prescribed mainly as a compounded peptide.
Evidence at a glance
Sermorelin has real human clinical history: it was an FDA-approved drug (Geref) for diagnosing and treating childhood GH deficiency. However, its popular modern uses (anti-aging, recovery, sleep, body composition in adults) rest on smaller studies and extrapolation, not large modern outcome trials. The brand was discontinued for commercial reasons in 2008. See Evidence Grading Explained and the Disclaimer.
Key Takeaways
- A GHRH analog — specifically GHRH(1-29) amide, the shortest fragment that retains full activity.
- Works upstream of the pituitary: it tells your own gland to release GH, so output stays subject to negative feedback (somatostatin), which is why it is considered more physiologic than injecting GH directly.
- Historically FDA-approved (brand Geref, 1997); brand voluntarily discontinued in 2008, approval formally withdrawn 2009 — not for safety reasons. All sermorelin in 2026 is compounded.
- Often combined with a GHRP/ghrelin mimetic like Ipamorelin for a synergistic pulse — conceptually similar to CJC-1295 + Ipamorelin.
- A common “entry-level” GH peptide in wellness clinics; positioned as gentler than MK-677 or direct HGH.
What Is It
Sermorelin is a synthetic 29-amino-acid peptide identical to the biologically active N-terminal fragment of human growth-hormone-releasing hormone (GHRH). Native GHRH is 44 amino acids long, but the first 29 residues — GHRH(1-29) — carry essentially all of the receptor-binding and GH-releasing activity, so sermorelin reproduces that fragment as a C-terminal amide.
Unlike injected recombinant HGH, sermorelin does not supply growth hormone. Instead it binds the GHRH receptor on the anterior pituitary and stimulates the gland to synthesize and secrete its own GH. Because that release remains under the body’s normal feedback control (including the brake hormone somatostatin), GH output tends to stay within a more physiologic, pulsatile range — a frequently cited theoretical safety advantage.
Mechanism of Action
- GHRH-receptor agonism (established) — binds GHRHR on pituitary somatotrophs, raising cAMP and triggering GH synthesis and pulsatile release.
- Preserved feedback loop (established physiology) — because the pituitary, not an external source, supplies the GH, somatostatin and IGF-1 feedback still limit excess output.
- Downstream IGF-1 rise (established) — the released GH stimulates hepatic IGF-1, the mediator of most growth/anabolic effects (compare IGF-1 LR3, which supplies IGF-1 directly).
- Sleep architecture (plausible) — GH secretion is naturally tied to slow-wave sleep; supporting nighttime GH pulses is the rationale behind sleep/recovery claims, though direct sleep-outcome trials are limited.
Limitations
Sermorelin’s effect depends on a functioning pituitary; it cannot help where the gland itself is the problem. Its modern adult “wellness” use is largely extrapolated from its approved pediatric/diagnostic history rather than confirmed by large adult outcome trials.
Evidence by Outcome
| Outcome | Evidence | Notes |
|---|---|---|
| GH deficiency (diagnosis/treatment, children) | Approved (historical) | Original FDA-approved indication as Geref |
| Raising GH / IGF-1 levels | Clinical | Reliably stimulates GH secretion in studies |
| Body composition / lean mass (adults) | Clinical / Anecdotal | Some supportive data; modern claims largely extrapolated |
| Sleep quality | Anecdotal / Preclinical | Tied to GH–slow-wave-sleep link; few direct trials |
| Recovery / general “anti-aging” | Anecdotal | Widely marketed; lacks large modern RCTs |
Reported Dosing
Not medical advice
Sermorelin is a prescription product; dosing should come from a clinician. Figures below are as commonly reported in clinical/compounding contexts, not a recommendation. See Reconstitution & Dosing Math and Injection Technique.
| Route | Dose (reported) | Frequency | Timing |
|---|---|---|---|
| Subcutaneous | ~100–300 µg | Once daily | At bedtime (to align with nocturnal GH pulse) |
| Subcutaneous (with GHRP) | ~100–200 µg + a GHRP | Once daily | Bedtime; empty stomach |
Pharmacokinetics
Sermorelin has a very short plasma half-life (~10–20 minutes) because, like native GHRH, it is rapidly cleared by peptidases. This short action is intentional — it produces a brief GH pulse rather than sustained elevation, which is the physiologic rationale for once-daily bedtime dosing. This contrasts with long-acting GHRH analogs like CJC-1295 (with DAC) and with Tesamorelin. See Half-Life & Pharmacokinetics.
Side Effects & Risks
- Generally well tolerated in its clinical history; most common complaints are injection-site reactions (redness, swelling, pain).
- Reported systemic effects: flushing, headache, dizziness, nausea, altered taste, occasional drowsiness.
- Theoretical GH-axis effects with overuse — fluid retention, joint aches, carpal-tunnel-type symptoms, insulin-sensitivity changes — though these are less likely than with direct HGH because feedback is preserved.
- Use is not advised with active malignancy (GH/IGF-1 signaling concern) — a clinician decision.
- Compounding-source variability: identity and purity depend on the pharmacy/vendor. See Side Effects & Risk Management and Bloodwork & Monitoring.
Cycling
No rigid cycling standard exists. Clinic protocols often run sermorelin continuously for several months with periodic IGF-1 monitoring, then reassess. Some users cycle on/off to limit receptor adaptation, though sermorelin is less prone to tachyphylaxis than potent GHRPs like Hexarelin. See Cycling.
Stacks It Appears In
- Pairs conceptually with a GHRP/ghrelin mimetic such as Ipamorelin — the same logic as the CJC-1295 + Ipamorelin stack.
- Sometimes compared or rotated with MK-677 (oral GH secretagogue) and Tesamorelin.
Comparisons
- Sermorelin vs CJC-1295 — same GHRH-analog family; CJC-1295 (with DAC) is long-acting, sermorelin is short-acting and more pulsatile.
- vs Ipamorelin / Hexarelin — those are GHRP/ghrelin-receptor agonists (different receptor); often combined with a GHRH analog like sermorelin.
- vs direct HGH — sermorelin stimulates endogenous GH and preserves feedback; HGH supplies it directly.
Sourcing & Quality
Because the FDA-approved brand is discontinued, sermorelin reaches patients via 503A/503B compounding pharmacies (prescription) or, less legitimately, as a gray-market “research chemical.” Compounded products are not FDA-approved finished drugs, so quality depends on the pharmacy. Evaluate before trusting any product: How to Read a CoA, Third-Party Testing, Red Flags & Scams. Reconstitution and storage: Reconstitution & Dosing Math, Storage & Handling. No vendors are endorsed here.
Legal & Regulatory Status
(As of 2026-06-05.) Sermorelin was FDA-approved in 1997 (brand Geref) for childhood GH deficiency and as a diagnostic agent. The manufacturer voluntarily discontinued Geref in 2008 for commercial reasons, and FDA withdrew the marketing approval (effective 2009) — explicitly not for safety or effectiveness concerns. Today sermorelin is legally available only by prescription through compounding pharmacies; there is no FDA-approved finished sermorelin product. It is a prescription drug, not an over-the-counter or freely-sold supplement, and may be prohibited in tested sport. See Regulatory & Legal Status.
FAQ
Is sermorelin FDA-approved? It was (brand Geref, 1997) but the brand was discontinued in 2008 and approval withdrawn in 2009 — not for safety reasons. In 2026 it is available only as a compounded prescription product, which is not itself FDA-approved.
How is it different from HGH? HGH is growth hormone. Sermorelin tells your own pituitary to make GH, keeping the body’s feedback controls intact — generally considered more physiologic.
Why dose at bedtime? Natural GH release peaks during deep sleep; dosing at night aims to reinforce that pulse.
What is it stacked with? Often a GHRP such as Ipamorelin, mirroring the CJC-1295 + Ipamorelin approach.
References
- U.S. FDA / Federal Register (2013). “Determination That GEREF (Sermorelin Acetate) Injection… Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness.” — confirms 2008 discontinuation and basis.
- Walker R.F. (2006). “Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?” Clinical Interventions in Aging.
- Prakash A., Goa K.L. (1999). “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.” BioDrugs.
- Sermorelin — Wikipedia (regulatory history, structure, pharmacology summary).
← Growth Hormone Secretagogues · Home Educational information only — not medical advice. See Disclaimer.